USFDA concludes cGMP inspection at Cipla’s Bengaluru manufacturing facility

31 May 2025 Evaluate

United States Food and Drugs Administration (USFDA) has concluded current Good Manufacturing Practices (cGMP) inspection at Cipla’s manufacturing facility in Bommasandra, Bengaluru. The inspection conducted from May 26, 2025 to May 30, 2025. 

On conclusion of the inspection, the company received one observation in Form 483. The company will work closely with the USFDA and remains committed to address the observation comprehensively within stipulated time. 

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1500.10 -10.80 (-0.71%)
01-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.40
Dr. Reddys Lab 1253.60
Cipla 1500.10
Zydus Lifesciences 914.50
Lupin 2103.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×